Potent Small Molecule Inhibitors for HIV-1 Protease

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	64752
Categories	Medical/Health Pharmaceuticals
Keywords	Darunavir Drug Resistance HIV/AIDS Medical/Health Pharmaceuticals Protease Inhibitors
Public Abstract	Advances in the treatment of HIV/AIDS with HIV-1 protease inhibitors in combination with reverse transcriptase inhibitors, known as highly active antiretroviral therapy (HAART), has resulted in improved life expectancy and significantly reduced HIV/AIDS-related mortality in the developed world. Unfortunately, HAART suffers from adverse drug side effects, poor oral bioavailability, and drug interactions. Also, drug-resistant HIV-1 variants have begun to emerge. Development of antiretroviral therapy with broad-spectrum activity and minimal side effects is needed for current and future HIV/AIDS treatment. Purdue University researchers have developed Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naive and -experienced adults and adolescents. It is also used in patients with drug-resistant HIV. The researchers have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad spectrum activity against highly cross-resistant mutant. Advantages: -Decreased adverse side effects -Effective against multidrug resistant HIV-1 variants -Improved bioavailability -Superior pharmacokinetic properties Potential Applications: -Medical/Healthcare -Pharmaceuticals -Drug Development -AIDS/HIV Treatment
People	Ghosh, Arun K (Project leader)
Intellectual Property	Application Date Jan 16, 2014 Type DIV-Patent Country of Filing United States Patent Number 9,359,317 Issue Date Jun 7, 2016 Application Date Jun 6, 2016 Type DIV-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jul 14, 2010 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jan 16, 2009 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Jan 16, 2009 Type NATL-Patent Country of Filing European Patent Patent Number (None) Issue Date (None) Application Date Jul 25, 2008 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jan 17, 2008 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Dec 5, 2006 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org